<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573702</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 1123</org_study_id>
    <nct_id>NCT01573702</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)</brief_title>
  <official_title>Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Progression free survival after locally ablative therapy and erlotinib in EGFR patients
      progressed after EGFR-TKI therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

      - To estimate progression free survival (PFS) after locally ablative therapy and erlotinib
      in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy

      Secondary Objectives

        -  To evaluate local control of sites previously progressive on erlotinib following SRS
           followed by erlotinib

        -  To estimate overall survival (OS) after locally ablative therapy and erlotinib in
           EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy

        -  To characterize the toxicity of SRS

        -  To characterize the toxicity of erlotinib when preceded by SRS

      Exploratory Objectives

        -  To explore if VeriStrat results following completion of SRS are associated with longer
           PFS or OS after re-initiation of erlotinib

        -  To explore if VeriStat results following completion of SRS are associated with longer
           PFS or OS after re-initiation of erlotinib

        -  To explore whether &quot;poor&quot; VeriStat signatures every turn to &quot;good&quot; signatures with the
           study therapy, and to explore PFS and OS of patients whose signature changes

        -  To utilize the full NMR peaks from MALDI-TOF to generate hypotheses regarding
           alternative signatures for evaluation and novel biomarkers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival in EGFR-mutant after erlotinib</measure>
    <time_frame>Initiation of Stereostatic Radiotherapy every 6 to 12 weeks until progression</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Progression free survival (PFS) after locally ablative therapy and erlotinib in EGFR-mutant NSCLC patients who progressed on prior EGFR-TKI therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sites progressing on erlotinib following Stereotactic Radiosurgery</measure>
    <time_frame>Initiation of Stereostatic Radiotherapy every 6 to 12 weeks until progression</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate local control of sites previously progressive on erlotinib following SRS followed by erlotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression after Stereotactic Radiosurgery</measure>
    <time_frame>Initiation of Stereostatic Radiosurgery every 6 to 12 weeks until progression</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate local control of sites previously on erlotinib following SRS followed by erlotinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm Study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereostatic Radiosurgery</intervention_name>
    <description>21 Gy daily for 5 days</description>
    <arm_group_label>Single Arm Study</arm_group_label>
    <other_name>Cyberknife</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg once daily</description>
    <arm_group_label>Single Arm Study</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  18 years of age or older

          -  Histologically or cytologically confirmed stge IV EGFR-mutant NSCLC

          -  History of previous response to EGFR-TKI defined by a RECIST 1.1 criteria

          -  Progressive disease following EGFR-TKI therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate organ and marrow function

          -  Negative urine or serum pregnancy test for female patients

          -  Patients who can have children must agree to adequate contraception

        Exclusion Criteria:

          -  Unresolved chronic toxicities greater than 2, measured by CTCAE v4

          -  Treatment with any FDA approved or experimental cancer treatment following
             progression on EGFR-TKI

          -  Any history of previous greater than grade 3 toxicity attributable to erlotinib

          -  Pregnant or lactating female

          -  Any previous radiation to sites of planned Stereostatic Radiosurgery

          -  History of another malignancy

          -  Concomitant anticancer therapy, immunotherapy, or radiation therapy (within 4 weeks)

          -  Evidence of severe or uncontrolled systemic diseases

          -  Known hypersensitivity reaction or idiosyncrasy to erlotinib

          -  Psychological, familial, sociological, or geographical conditions

          -  Any other condition in investigator's opinion jeopardize compliance with protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC at Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jared Weiss, MD</last_name>
    <phone>919-843-7718</phone>
    <email>jared_weiss@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dale Flowers, RN</last_name>
    <phone>919-966-7359</phone>
    <email>dale_flowers@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Gubens, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eamon Berge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>STO Taussig Cancer Center; Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathan Pennell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hossein Borghaei, MS, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liza Villaruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Howard West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 9, 2016</lastchanged_date>
  <firstreceived_date>April 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>EGFR mutant</keyword>
  <keyword>Phase II</keyword>
  <keyword>erlotinib</keyword>
  <keyword>tarceva</keyword>
  <keyword>cyberknife</keyword>
  <keyword>Lineberger</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
